Jivi, antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age …
Show more
See More
Jivi is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, polyethylene glycol (PEG), mouse or hamster proteins, or other constituents of the …
Show more
See More
INDICATIONS. Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents …
Show more
See More
Sep 07, 2018 . Jivi ® [antihemophilic factor (recombinant), PEGylated-aucl] Lyophilized Powder for Solution, for Intravenous Use. DESCRIPTION. Jivi [antihemophilic factor (recombinant), …
Gray: 3000 IU with 2.5 mL SWFI
Red: 1000 IU with 2.5 mL SWFI
Green: 500 IU with 2.5 mL SWFI
Yellow: 2000 IU with 2.5 mL SWFI
Show more
See More
Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in …
Show more
See More
ЏИВИ ДОО Гевгелија е компанија основана во 1992 година, кога започна со трговија на аудио-видео опрема и апарати за домаќинство. Од самиот почеток ЏИВИ остварува …
Show more
See More
Usage Area. All meters & gateways for countries permitting 868 MHz (i.e. CEPT countries as the EU & EEA) including all German electricity meters (also with BSI requirement). Battery …
Jivi
Show more
See More
Lääkeinfo.fi - Suomessa myytävien lääkevalmisteiden pakkausselosteet. Jivi injektiokuiva-aine ja liuotin, liuosta varten 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU
Show more
See More
Oct 26, 2018 . Jivi, formerly known as BAY94-9027, is a man-made version of the clotting factor VIII (rFVIII) that was designed specifically to be more stable and have prolonged action than …
Show more
See More
Specification. Initially the I2C Bus specification had been written by Philips Semiconductors. This company became NXP Semiconductors which now it the stakeholder of the I2C bus …
Jivi
Show more
See More
The RapidIO 3.0 specification, know as 10xN, increases single lane speed to 10 Gbit/s and support up to 16 lanes operating in parallel for up to 160 Gbps.
Jivi
Show more
See More
What is Jivi? Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A (congenital Factor VIII deficiency). Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older ) with hemophilia A.
1-800-FDA-1088. Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:
The administration of Jivi increases plasma levels of Factor VIII and can temporarily correct the coagulation defect in hemophilia A patients. The PK of Jivi was evaluated in two cohorts after single doses of 25 IU/kg and 60 IU/kg and after 25 IU/kg given twice weekly and 60 IU/kg given once weekly for 8 weeks.
3 DOSAGE FORMS AND STRENGTHS Jivi is available as a white to slightly yellow lyophilized powder in single-use glass vials containing nominally 500, 1000, 2000, or 3000 IU of Factor VIII potency per vial. 6 Each vial of Jivi is labeled with actual Factor VIII potency expressed in IU determined using a chromogenic substrate assay.
Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A.
The European Medicines Agency decided that Jivi’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.
Developed by Bayer, it is given as an infusion into the bloodstream and also can be used on-demand in response to a bleed. How does Jivi work? Hemophilia type A is an inherited condition that results due to a mutation in the coagulation factor 8, or F8 gene.
Jivi antihemophilic factor (previously BAY 94-9027) is an approved prophylactic or preventive treatment for hemophilia type A patients, ages 12 or older. Developed by Bayer, it is given as an infusion into the bloodstream and also can be used on-demand in response to a bleed.